Haptoglobin-β chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer

International Journal of Cancer

Volumn 123, Issue 3, 2008, Pages 633-640

  Saito, Seiichi ^a   Murayama, Yasuko ^a   Pan, Yuzhuo ^a   Taima, Takenobu ^a   Fujimura, Tsutomu ^b,c,d   Murayama, Kimie ^b,c   Sadilek, Martin ^c   Egawa, Shin ^e   Ueno, Seiji ^a   Ito, Akihiro ^a   Ishidoya, Shigeto ^a   Nakagawa, Haruo ^a   Kato, Masanori ^a   Satoh, Makoto ^f   Endoh, Mareyuki ^a   Arai, Yoichi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d JUNTENDO UNIVERSITY   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Sen en Hospital   (Japan)

Author keywords

Haptoglobin; Prostate cancer; RM2; Serum marker

Indexed keywords

EPITOPE; HAPTOGLOBIN; HAPTOGLOBIN BETA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RM2; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; EARLY CANCER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY; PROTEOMICS; SENSITIVITY AND SPECIFICITY; UROGENITAL TRACT CANCER; WESTERN BLOTTING;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HAPTOGLOBINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 46049087346     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23490     Document Type: Article

References (32)

1. Carter HB, Partin AW. Diagnosis and staging of prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's urology, 8th edn. Philadelphia: Saunders, 2002.3209-226.
2. Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am 2003;30:677-86.
3. Canto EI, Shariat SF, Slawin KM. Biochemical staging of prostate cancer. Urol Clin North Am 2003;30:263-77.
4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Pames HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Clotman CA. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
5. Adam B-L, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL, Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostatic hyperplasia. Cancer Res 2002;62:3609-14.
6. Lehman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, Getzenberg RH. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007;69:714-20.
7. Saito S, Levery SB, Salyan MEK, Goldberg RI, Hakomori S. Common tetrasaccharide epitope NeuAcalpha2-3Galbeta1-3(NeuAcalpha2-6)GalNAc, presented by different carrier glycosylceramides or O-linked peptides, is recognized by different antibodies and ligands having distinct specificities. J Biol Chem 1994;269:5644-52.
8. Ito A, Levery SB, Saito S, Satoh M, Hakomori S. A novel ganglioside isolated from renal cell carcinoma. J Biol Chem 2001;276:16695-703.
9. 4) as a new marker for prostate cancer. Int J Cancer 2005;115:105-13.
10. Flemming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, eds. American Joint Committee on Cancer Staging Manual, 5th edn. Philadelphia: Lippincott; 1997:219.
11. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon (France): IARC Press, 2004:179.
12. Saito S, Orikasa S, Ohyama C, Satoh M, Fukushi Y. Changes in glycolipids in human renal-cell carcinoma and their clinical significance. Int J Cancer 1991;49:329-34.
13. Mineki R, Taka H, Fujimura T, Kikkawa M, Shindo N, Murayama K. In situ alkylation with acrylamide for identification of cysteinyl residues in proteins during one- and two-dimensional sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Proteomics 2002;2: 1672-81.
14. Aoki H, Satoh M, Mitsuzuka K, Ito A, Saito S, Funato T, Endoh M, Takahashi T, Arai Y. Inhibition of motility and invasiveness of renal cell carcinoma induced by short interference RNA transfection of β 1,4 GalNAc transferase. FEBS Lett 2004;567:203-8.
15. Saito S, Aoki H, Ito A, Ueno S, Wada T, Mitsuzuka K, Satoh M, Arai Y, Miyagi T. Human α 2,3-sialyltransferase (ST3Gal II) is a stage-specific embryonic antigen-4 synthase. J Biol Chem 2003;278:26474-79.
16. Fujimura T, Shinohara Y, Tissot B, Pang P-C, Kurogochi M, Saito S, Aarai Y, Sadilek M, Murayama K, Dell A, Nishimura S, Hakomori S. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer 2008;122:39-49.
17. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;42:1589-1600.
18. Kurosky A, Barnett DR, Lee TH, Touchstone B, Hay RE, Arnott MS, Bowman BH, Fitch WM. Covalent structure of human haptoglobin: a serine protease homolog. Proc Natl Acad Sci USA 1980;77:3388-92.
19. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660-66.
20. Liu T, Qian WJ, Gritsenko MA, Camp DG, II, Monroe ME, Moore RJ, Smith RD. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res 2005;4:2070-80.
21. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, Mueller CA, Flad T. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alfa in renal cancer patients. Lab Invest 2004;84:845-56.
22. Oh S-K, Kim S-H, Walker JE. Interference with immune response at the level of generating effector cells by tumor-associated haptoglobin. J Natl Cancer Inst 1990;82:934-40.
23. McNeal JE, Redwine EA, Freiha ES, Stamey TA. Zonal distribution of prostate adenocarcinoma. Correlation with histologic pattern and distribution of spread. Am J Surg Pathol 1988;12:897-906.
24. Wang Y, Kinzie E, Berger FG, Lim S-K, Baumann H. Haptoglobin, an inflammation-inducible plasma protein. Redox Rep 2001;6:379-85.
25. Okuyama N, Ide Y, Nakano M, Nakagawa K, Yamanaka K, Moriwaki K, Murata K, Ohigashi H, Yokoyama S, Eguchi H, Ishikawa O, Ito T, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006;118:2803-8.
26. Oliviero S, Cortese R. The human haptoglobin gene promoter: interleukin-6-responsive elements interact with a DNA-binding protein induced by interleukin-6. EMBO J 1989;8:1145-51.
27. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003;9:2904-11.
28. Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 2005;5:4625-36.
29. Gonçalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M, Bardou VJ, Houvenaegel G, Jacquemier J, Granjeaud S, Meng X-Y, Fung ET, et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006;25:981-9.
30. Kwak J-Y, Ma T-Z, Yoo M-J, Choi BH, Kim H-G, Kim S-R, Yim C-Y, Kwak Y-G. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol 2004;32:836-42.
31. Ang IL, Poon TCW, Lai PBS, Chan ATC, Ngai S-M, Hul AY, Johnson PJ, Sung JJ. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res 2006;5:2691-700.
32. Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT, Salgia R. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 2004;24:1031-8.